Is Revvity Stock Underperforming the Dow?

Valued at a market cap of $11.2 billion, Revvity, Inc. (RVTY) is a provider of health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Based in Waltham, Massachusetts, the company operates through Life Sciences and Diagnostics segments.

Companies worth $10 billion or more are generally classified as “large-cap” stocks, and Revvity fits this description perfectly. The company provides cutting-edge solutions across diagnostics, life sciences research, and applied markets, offering technologies such as imaging systems, reagents, software, and lab services. 

Revvity stock has dropped 26.7% from its 52-week high of $129.50. Shares of RVTY have declined 11.5% over the past three months, lagging behind the broader Dow Jones Industrials Average's ($DOWI) 1.4% gain.

On a YTD basis, RVTY stock has dipped 14.9%, whereas DOWI has risen marginally. In addition, shares of Revvity have decreased 12.1% over the past 52 weeks, underperforming the Dow Jones’ 8.8% return over the same time frame. 

Despite recent fluctuations, the stock has been trading below its 50-day and 200-day moving averages since early February.

Shares of Revvity rose marginally following the release of its solid Q1 2025 results on Apr. 28. The company reported revenue of $664.8 million, a 2.3% increase from the year-ago quarter, driven by growth across both segments and surpassing the consensus estimate. Adjusted EPS from continuing operations rose 3.1% year-over-year to $1.01, beating Wall Street expectations.

Looking ahead, Revvity raised its full-year 2025 revenue guidance to a range of $2.8 billion to $2.9 billion, while reaffirming its adjusted EPS outlook between $4.90 and $5.00, which further lifted investor sentiment.

However, rival Labcorp Holdings Inc. (LH) has outpaced RVTY stock. LH stock has soared 13.8% on a YTD basis and 27.2% over the past 52 weeks.

Despite RVTY’s underperformance relative to the Dow, analysts have a moderately optimistic outlook. With 17 analysts covering the stock, the consensus rating is “Moderate Buy,” and it is currently trading below the mean price target of $119.12.